US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ArriVent BioPharma

31.03

+0.52001.70%

Post-market: 31.030.00000.00%16:10 EDT

Volume:465.36K

Turnover:14.35M

Market Cap:1.53B

PE:-8.39

High:31.39

Open:30.58

Low:30.22

Close:30.51

52wk High:35.83

52wk Low:17.00

Shares:49.31M

Float Shares:32.11M

Volume Ratio:1.29

T/O Rate:1.45%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.6975

EPS(LYR):-4.3239

ROE:-53.25%

ROA:-33.11%

PB:4.17

PE(LYR):-7.18

Loading ...

Overview Company News Filings

LifeSci Capital Remains a Buy on ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma Is Maintained at Buy by Citigroup

ArriVent BioPharma Updates At-The-Market Equity Offering Program

ArriVent Biopharma launches ATM offering for up to $250 million via Jefferies

Arrivent Biopharma Inc - Enters Open Market Sale Agreement for Offer and Sell Common Stock up to $250 Mln - SEC Filing

THOMSON REUTERS

ArriVent Biopharma posts corporate presentation on late-stage oncology pipeline, firmonertinib lead program

ArriVent BioPharma Inc reports results for the quarter ended March 31 - Earnings Summary

ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate

Benzinga Earnings

ArriVent Q1 net loss narrows 32.7% to $43.3 million

Arrivent Biopharma Reports First Quarter 2026 Financial Results

THOMSON REUTERS

Press Release: ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent BioPharma Inc expected to post a loss of 89 cents a share - Earnings Preview

H.C. Wainwright Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)

ArriVent Biopharma announces FDA clearance of ARR-002 NDA

BRIEF-Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial Cancers

ArriVent wins FDA IND clearance for ARR-002 cancer antibody-drug conjugate

Arrivent Biopharma Inc - Phase 1 Initiation for Arr-002 Expected in Second Half of 2026

THOMSON REUTERS

Arrivent Announces Ind Clearance for Novel Tetravalent Muc16/Napi2b Targeting ADC Arr-002 With Initial Focus in Ovarian and Endometrial Cancers

THOMSON REUTERS

ArriVent Biopharma announces annual shareholder meeting via webcast

ArriVent BioPharma Is Maintained at Buy by Citigroup

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/AVBP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":31.03,"timestamp":1788465600000,"preClose":30.51,"halted":0,"volume":465358,"hourTrading":{"tag":"盘后","latestPrice":31.03,"preClose":31.03,"latestTime":"16:10 EDT","volume":7207,"amount":223633.21000000002,"timestamp":1788466205423,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.017043592264831188,"floatShares":32106300,"shares":49307729,"eps":-3.697539,"marketStatus":"Post-Mkt","change":0.52,"latestTime":"09-03 17:19:17 EDT","open":30.58,"high":31.39,"low":30.22,"amount":14345942,"amplitude":0.038348,"askPrice":31.5,"askSize":47,"bidPrice":28,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-3.697539,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788480000000},"marketStatusCode":4,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":30.51,"preHourTrading":{"tag":"盘前","latestPrice":30.7,"preClose":30.51,"latestTime":"09:22 EDT","volume":297,"amount":9095.528178,"timestamp":1788441749437,"change":0.19,"changeRate":0.006227,"amplitude":0.107506},"postHourTrading":{"tag":"盘后","latestPrice":31.03,"preClose":31.03,"latestTime":"16:10 EDT","volume":7207,"amount":223633.21000000002,"timestamp":1788466205423,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.290535,"impliedVol":1.1827,"impliedVolPercentile":0.5317},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","floatShares":32106300,"roa":"-33.11%","roe":"-53.25%","lyrEps":-4.323888,"volumeRatio":1.290535,"shares":49307729,"dividePrice":0,"high":31.39,"amplitude":0.038348,"preClose":30.51,"low":30.22,"week52Low":17,"pbRate":"4.17","week52High":35.83,"institutionHeld":0,"latestPrice":31.03,"committee":-0.807692,"eps":-3.697539,"divideRate":0,"volume":465358,"delay":0,"ttmEps":-3.697539,"open":30.58,"prevYearClose":20.12,"prevWeekClose":30.17,"prevMonthClose":30.05,"prevQuarterClose":34.74,"fiveDayClose":31,"twentyDayClose":31.01,"sixtyDayClose":30.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"AVBP","fiscalQuarterEnding":"2026/06","expectedEps":-0.98,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.05},{"market":"US","date":"2026-05-11","symbol":"AVBP","fiscalQuarterEnding":"2026/03","expectedEps":-0.88,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-0.96},{"market":"US","date":"2026-03-05","symbol":"AVBP","fiscalQuarterEnding":"2025/12","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2025-11-10","symbol":"AVBP","fiscalQuarterEnding":"2025/09","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.83},{"market":"US","date":"2025-08-11","symbol":"AVBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.7,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":-0.9}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.5833,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1766462400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVBP","date":"2026-09-02","current":-8.392068,"percent":0.402844,"low":-15.980041,"twenty":-11.023236,"median":-8.373482,"eighty":-6.007177,"high":-4.80343,"avg":-8.585054,"sd":2.46686,"marketCap":1486628029},"quantilePoints":[{"date":"2024-01-26","current":-15.452095,"twenty":-15.452095,"median":-15.452095,"eighty":-15.452095,"marketCap":905214654},{"date":"2024-02-02","current":-11.990156,"twenty":-12.001066,"median":-11.872873,"eighty":-10.91006,"marketCap":702407320},{"date":"2024-02-09","current":-12.548731,"twenty":-12.548731,"median":-12.001066,"eighty":-11.75559,"marketCap":735129780},{"date":"2024-02-16","current":-12.588659,"twenty":-12.548731,"median":-12.126596,"eighty":-11.919241,"marketCap":737468829},{"date":"2024-02-23","current":-11.219707,"twenty":-12.556717,"median":-11.998256,"eighty":-11.67237,"marketCap":657272853},{"date":"2024-03-01","current":-12.286349,"twenty":-12.548731,"median":-11.990156,"eighty":-11.204877,"marketCap":719758884},{"date":"2024-03-08","current":-11.464977,"twenty":-12.548731,"median":-11.964074,"eighty":-11.315533,"marketCap":671641299},{"date":"2024-03-15","current":-10.59227,"twenty":-12.5031,"median":-11.767288,"eighty":-11.121598,"marketCap":620516364},{"date":"2024-03-22","current":-10.386927,"twenty":-12.327418,"median":-11.658912,"eighty":-10.920492,"marketCap":608486967},{"date":"2024-03-28","current":-10.267144,"twenty":-12.279504,"median":-11.507757,"eighty":-10.718898,"marketCap":601469820},{"date":"2024-04-05","current":-8.84046,"twenty":-12.261251,"median":-11.265338,"eighty":-10.410884,"marketCap":612935625},{"date":"2024-04-12","current":-8.536116,"twenty":-12.10149,"median":-11.165519,"eighty":-9.961411,"marketCap":591834562},{"date":"2024-04-19","current":-7.487821,"twenty":-11.997694,"median":-11.025772,"eighty":-8.805678,"marketCap":519153125},{"date":"2024-04-26","current":-7.507145,"twenty":-11.992272,"median":-10.91658,"eighty":-8.501334,"marketCap":520492875},{"date":"2024-05-03","current":-8.115832,"twenty":-11.986485,"median":-10.803317,"eighty":-8.191193,"marketCap":562695000},{"date":"2024-05-10","current":-8.079495,"twenty":-11.960082,"median":-10.543786,"eighty":-8.115832,"marketCap":602552562},{"date":"2024-05-17","current":-9.049573,"twenty":-11.929189,"median":-10.386927,"eighty":-8.101297,"marketCap":674899062},{"date":"2024-05-24","current":-8.479203,"twenty":-11.828069,"median":-10.210104,"eighty":-8.115832,"marketCap":632362000},{"date":"2024-05-31","current":-8.739687,"twenty":-11.762609,"median":-9.361752,"eighty":-8.133223,"marketCap":651788375},{"date":"2024-06-07","current":-8.241175,"twenty":-11.7192,"median":-8.959751,"eighty":-8.180566,"marketCap":614610312},{"date":"2024-06-14","current":-8.456747,"twenty":-11.662334,"median":-8.912923,"eighty":-8.216398,"marketCap":630687312},{"date":"2024-06-21","current":-7.455231,"twenty":-11.653208,"median":-8.84046,"eighty":-8.15931,"marketCap":555996250},{"date":"2024-06-28","current":-7.81452,"twenty":-11.61214,"median":-8.79358,"eighty":-8.133223,"marketCap":582791250},{"date":"2024-07-05","current":-8.205246,"twenty":-11.533425,"median":-8.753505,"eighty":-8.152944,"marketCap":611930812},{"date":"2024-07-12","current":-8.268121,"twenty":-11.43988,"median":-8.706383,"eighty":-8.152944,"marketCap":616619937},{"date":"2024-07-15","current":-8.259139,"twenty":-11.414782,"median":-8.695535,"eighty":-8.154535,"marketCap":615950062},{"date":"2024-08-02","current":-9.655872,"twenty":-11.389685,"median":-8.706383,"eighty":-8.156127,"marketCap":720115625},{"date":"2024-08-09","current":-10.262171,"twenty":-11.294999,"median":-8.753505,"eighty":-8.186872,"marketCap":765332187},{"date":"2024-08-16","current":-10.701201,"twenty":-11.237959,"median":-8.81702,"eighty":-8.205246,"marketCap":801359406},{"date":"2024-08-23","current":-10.705686,"twenty":-11.199173,"median":-8.912923,"eighty":-8.209568,"marketCap":801695265},{"date":"2024-08-30","current":-12.010819,"twenty":-11.389685,"median":-8.993434,"eighty":-8.224295,"marketCap":899430214},{"date":"2024-09-06","current":-11.93009,"twenty":-11.657877,"median":-9.253918,"eighty":-8.235785,"marketCap":893384753},{"date":"2024-09-13","current":-10.669806,"twenty":-11.694732,"median":-9.655872,"eighty":-8.248361,"marketCap":799008394},{"date":"2024-09-20","current":-10.85369,"twenty":-11.663166,"median":-9.763659,"eighty":-8.262732,"marketCap":812778610},{"date":"2024-09-27","current":-10.544226,"twenty":-11.657877,"median":-10.060071,"eighty":-8.269917,"marketCap":789604344},{"date":"2024-10-04","current":-11.49056,"twenty":-11.61214,"median":-10.208101,"eighty":-8.279798,"marketCap":860470578},{"date":"2024-10-11","current":-12.463804,"twenty":-11.739278,"median":-10.315491,"eighty":-8.299559,"marketCap":933351966},{"date":"2024-10-18","current":-13.002004,"twenty":-11.938503,"median":-10.371883,"eighty":-8.317243,"marketCap":973655038},{"date":"2024-10-25","current":-13.912458,"twenty":-11.99333,"median":-10.426855,"eighty":-8.325491,"marketCap":1041834400},{"date":"2024-10-31","current":-14.114283,"twenty":-12.114871,"median":-10.539741,"eighty":-8.328911,"marketCap":1056948052},{"date":"2024-11-08","current":-15.980041,"twenty":-12.249611,"median":-10.573379,"eighty":-8.330997,"marketCap":1196665367},{"date":"2024-11-15","current":-11.674764,"twenty":-12.282511,"median":-10.59227,"eighty":-8.332793,"marketCap":946216280},{"date":"2024-11-22","current":-11.05527,"twenty":-12.272349,"median":-10.669806,"eighty":-8.342492,"marketCap":896007510},{"date":"2024-11-29","current":-12.456408,"twenty":-12.274941,"median":-10.685503,"eighty":-8.352544,"marketCap":1009566943},{"date":"2024-12-06","current":-11.870175,"twenty":-12.284404,"median":-10.712096,"eighty":-8.353452,"marketCap":962053946},{"date":"2024-12-13","current":-10.760075,"twenty":-12.274941,"median":-10.748293,"eighty":-8.371867,"marketCap":872082526},{"date":"2024-12-20","current":-10.664448,"twenty":-12.261979,"median":-10.759506,"eighty":-8.380399,"marketCap":864332179},{"date":"2024-12-27","current":-11.46688,"twenty":-12.254096,"median":-10.803317,"eighty":-8.380399,"marketCap":929367700},{"date":"2025-01-03","current":-11.421146,"twenty":-12.244582,"median":-10.85369,"eighty":-8.380399,"marketCap":925661012},{"date":"2025-01-10","current":-11.167527,"twenty":-12.234172,"median":-10.860965,"eighty":-8.382195,"marketCap":905105744},{"date":"2025-01-17","current":-10.177999,"twenty":-12.217129,"median":-10.850538,"eighty":-8.390279,"marketCap":824906501},{"date":"2025-01-24","current":-11.329677,"twenty":-12.196013,"median":-10.850538,"eighty":-8.405549,"marketCap":918247637},{"date":"2025-01-31","current":-12.09469,"twenty":-12.164539,"median":-10.860965,"eighty":-8.437266,"marketCap":980250413},{"date":"2025-02-07","current":-11.383727,"twenty":-12.161213,"median":-10.897572,"eighty":-8.450678,"marketCap":922628268},{"date":"2025-02-14","current":-11.16337,"twenty":-12.157147,"median":-10.9231,"eighty":-8.461238,"marketCap":904768772},{"date":"2025-02-21","current":-11.387884,"twenty":-12.140884,"median":-10.92545,"eighty":-8.479203,"marketCap":922965239},{"date":"2025-02-28","current":-9.8537,"twenty":-12.107163,"median":-10.91658,"eighty":-8.519623,"marketCap":798622715},{"date":"2025-03-07","current":-9.217439,"twenty":-12.09469,"median":-10.885085,"eighty":-8.536116,"marketCap":741893256},{"date":"2025-03-14","current":-9.192082,"twenty":-12.065586,"median":-10.857328,"eighty":-8.618427,"marketCap":739852284},{"date":"2025-03-21","current":-8.258082,"twenty":-12.010819,"median":-10.847386,"eighty":-8.519623,"marketCap":664676489},{"date":"2025-03-28","current":-7.848136,"twenty":-12.001066,"median":-10.781696,"eighty":-8.449161,"marketCap":631680778},{"date":"2025-04-04","current":-7.159258,"twenty":-11.995446,"median":-10.737081,"eighty":-8.380399,"marketCap":576234377},{"date":"2025-04-11","current":-7.125448,"twenty":-11.990156,"median":-10.711139,"eighty":-8.353452,"marketCap":573513081},{"date":"2025-04-17","current":-7.564978,"twenty":-11.988746,"median":-10.703443,"eighty":-8.330997,"marketCap":608889926},{"date":"2025-04-25","current":-8.94696,"twenty":-11.984909,"median":-10.669806,"eighty":-8.330476,"marketCap":720122890},{"date":"2025-05-02","current":-8.908923,"twenty":-11.976101,"median":-10.6604,"eighty":-8.330997,"marketCap":717061432},{"date":"2025-05-09","current":-8.353948,"twenty":-11.95416,"median":-10.580862,"eighty":-8.330997,"marketCap":672392561},{"date":"2025-05-16","current":-5.164444,"twenty":-11.945123,"median":-10.566696,"eighty":-8.323142,"marketCap":658249673},{"date":"2025-05-23","current":-5.537551,"twenty":-11.932894,"median":-10.539741,"eighty":-8.281274,"marketCap":705805133},{"date":"2025-05-30","current":-5.636867,"twenty":-11.923581,"median":-10.506711,"eighty":-8.258716,"marketCap":718463781},{"date":"2025-06-06","current":-6.29987,"twenty":-11.889801,"median":-10.45834,"eighty":-8.241176,"marketCap":802968806},{"date":"2025-06-13","current":-6.342817,"twenty":-11.86768,"median":-10.37894,"eighty":-8.205246,"marketCap":808442816},{"date":"2025-06-20","current":-6.681029,"twenty":-11.831093,"median":-10.360937,"eighty":-8.13004,"marketCap":851550643},{"date":"2025-06-27","current":-6.122711,"twenty":-11.774139,"median":-10.336565,"eighty":-8.056606,"marketCap":780388516},{"date":"2025-07-03","current":-5.951741,"twenty":-11.764948,"median":-10.291317,"eighty":-8.012114,"marketCap":758596999},{"date":"2025-07-11","current":-6.3128,"twenty":-11.752729,"median":-10.177999,"eighty":-7.877518,"marketCap":804616846},{"date":"2025-07-18","current":-6.510523,"twenty":-11.737545,"median":-10.15098,"eighty":-7.814365,"marketCap":829818191},{"date":"2025-07-25","current":-6.146598,"twenty":-11.721024,"median":-10.060071,"eighty":-7.74746,"marketCap":783433107},{"date":"2025-08-01","current":-5.590682,"twenty":-11.706801,"median":-9.819907,"eighty":-7.667253,"marketCap":712577152},{"date":"2025-08-08","current":-5.312724,"twenty":-11.672734,"median":-9.759167,"eighty":-7.57343,"marketCap":677149175},{"date":"2025-08-15","current":-5.522288,"twenty":-11.663891,"median":-9.64689,"eighty":-7.464633,"marketCap":755393737},{"date":"2025-08-22","current":-5.895976,"twenty":-11.659587,"median":-9.496371,"eighty":-7.205647,"marketCap":806510606},{"date":"2025-08-29","current":-5.697269,"twenty":-11.653822,"median":-9.38434,"eighty":-6.898922,"marketCap":779329414},{"date":"2025-09-05","current":-5.789208,"twenty":-11.653208,"median":-9.260758,"eighty":-6.705187,"marketCap":791905786},{"date":"2025-09-12","current":-5.640919,"twenty":-11.550537,"median":-9.192082,"eighty":-6.342817,"marketCap":771621314},{"date":"2025-09-19","current":-5.510425,"twenty":-11.49056,"median":-9.038346,"eighty":-6.3128,"marketCap":753770979},{"date":"2025-09-26","current":-5.092249,"twenty":-11.46688,"median":-8.984996,"eighty":-6.266951,"marketCap":696568768},{"date":"2025-10-03","current":-5.584569,"twenty":-11.464977,"median":-8.939882,"eighty":-6.203238,"marketCap":763913215},{"date":"2025-10-10","current":-6.266699,"twenty":-11.458565,"median":-8.908923,"eighty":-6.178119,"marketCap":857221786},{"date":"2025-10-17","current":-5.820349,"twenty":-11.441934,"median":-8.860202,"eighty":-6.17476,"marketCap":796165526},{"date":"2025-10-24","current":-5.365101,"twenty":-11.433619,"median":-8.84046,"eighty":-6.120027,"marketCap":733892196},{"date":"2025-10-31","current":-5.477801,"twenty":-11.433619,"median":-8.796928,"eighty":-6.098553,"marketCap":749308395},{"date":"2025-11-07","current":-5.454075,"twenty":-11.421146,"median":-8.757651,"eighty":-5.987916,"marketCap":746062880},{"date":"2025-11-14","current":-5.38103,"twenty":-11.41283,"median":-8.728459,"eighty":-5.931566,"marketCap":812417184},{"date":"2025-11-21","current":-5.484932,"twenty":-11.400357,"median":-8.689159,"eighty":-5.895976,"marketCap":828104101},{"date":"2025-11-28","current":-6.2724,"twenty":-11.397031,"median":-8.627903,"eighty":-5.884113,"marketCap":946994421},{"date":"2025-12-05","current":-6.657931,"twenty":-11.389547,"median":-8.556032,"eighty":-5.884113,"marketCap":1005201140},{"date":"2025-12-12","current":-6.649728,"twenty":-11.384558,"median":-8.523142,"eighty":-5.893603,"marketCap":1003962699},{"date":"2025-12-19","current":-5.788435,"twenty":-11.375905,"median":-8.467975,"eighty":-5.893603,"marketCap":873926412},{"date":"2025-12-26","current":-6.094673,"twenty":-11.359859,"median":-8.441726,"eighty":-5.901564,"marketCap":920161536},{"date":"2026-01-02","current":-5.501338,"twenty":-11.346075,"median":-8.391627,"eighty":-5.884113,"marketCap":830580983},{"date":"2026-01-09","current":-5.364625,"twenty":-11.337228,"median":-8.380399,"eighty":-5.844354,"marketCap":809940302},{"date":"2026-01-16","current":-5.988037,"twenty":-11.332171,"median":-8.373482,"eighty":-5.835858,"marketCap":904061805},{"date":"2026-01-23","current":-6.890344,"twenty":-11.326351,"median":-8.3537,"eighty":-5.833294,"marketCap":1040290297},{"date":"2026-01-30","current":-6.152093,"twenty":-11.304731,"median":-8.339979,"eighty":-5.843953,"marketCap":928830622},{"date":"2026-02-06","current":-5.837652,"twenty":-11.270243,"median":-8.329694,"eighty":-5.843953,"marketCap":881357057},{"date":"2026-02-13","current":-6.130218,"twenty":-11.263238,"median":-8.321475,"eighty":-5.843953,"marketCap":925528113},{"date":"2026-02-20","current":-6.313414,"twenty":-11.254838,"median":-8.290577,"eighty":-5.845558,"marketCap":953186625},{"date":"2026-02-27","current":-6.351694,"twenty":-11.246523,"median":-8.270367,"eighty":-5.848589,"marketCap":958966016},{"date":"2026-03-06","current":-6.710988,"twenty":-11.219707,"median":-8.258082,"eighty":-5.878182,"marketCap":1116090955},{"date":"2026-03-13","current":-6.40401,"twenty":-11.204946,"median":-8.245403,"eighty":-5.8814,"marketCap":1065038082},{"date":"2026-03-20","current":-6.07577,"twenty":-11.192473,"median":-8.232192,"eighty":-5.884113,"marketCap":1010449078},{"date":"2026-03-27","current":-5.79537,"twenty":-11.188316,"median":-8.205246,"eighty":-5.878182,"marketCap":963816367},{"date":"2026-04-02","current":-6.437233,"twenty":-11.18605,"median":-8.155331,"eighty":-5.851728,"marketCap":1070563284},{"date":"2026-04-10","current":-7.242551,"twenty":-11.184423,"median":-8.115832,"eighty":-5.873048,"marketCap":1204494199},{"date":"2026-04-17","current":-7.869796,"twenty":-11.184158,"median":-8.05762,"eighty":-5.880756,"marketCap":1308810027},{"date":"2026-04-24","current":-8.239233,"twenty":-11.170853,"median":-8.079495,"eighty":-5.88357,"marketCap":1370250282},{"date":"2026-05-01","current":-8.263153,"twenty":-11.164201,"median":-8.071094,"eighty":-5.884113,"marketCap":1374228427},{"date":"2026-05-08","current":-8.043687,"twenty":-11.160044,"median":-8.062693,"eighty":-5.892853,"marketCap":1337729551},{"date":"2026-05-15","current":-9.113539,"twenty":-11.148286,"median":-8.082287,"eighty":-5.895788,"marketCap":1323659453},{"date":"2026-05-22","current":-8.658182,"twenty":-11.130931,"median":-8.115832,"eighty":-5.903426,"marketCap":1257523056},{"date":"2026-05-29","current":-8.648562,"twenty":-11.121131,"median":-8.15931,"eighty":-5.909002,"marketCap":1256125808},{"date":"2026-06-05","current":-10.611083,"twenty":-11.112406,"median":-8.208286,"eighty":-5.914633,"marketCap":1541164367},{"date":"2026-06-12","current":-9.684337,"twenty":-11.089363,"median":-8.224914,"eighty":-5.923855,"marketCap":1406562825},{"date":"2026-06-18","current":-10.056318,"twenty":-11.074395,"median":-8.233917,"eighty":-5.929786,"marketCap":1460589742},{"date":"2026-06-26","current":-10.846778,"twenty":-11.071901,"median":-8.241176,"eighty":-5.939636,"marketCap":1575396939},{"date":"2026-07-02","current":-11.063233,"twenty":-11.071901,"median":-8.253856,"eighty":-5.951741,"marketCap":1606835016},{"date":"2026-07-10","current":-10.797074,"twenty":-11.071901,"median":-8.258372,"eighty":-5.954231,"marketCap":1568177825},{"date":"2026-07-17","current":-10.505261,"twenty":-11.071901,"median":-8.265637,"eighty":-5.966771,"marketCap":1525794641},{"date":"2026-07-24","current":-10.11404,"twenty":-11.070167,"median":-8.283439,"eighty":-5.979263,"marketCap":1468973229},{"date":"2026-07-31","current":-9.831847,"twenty":-11.063233,"median":-8.313032,"eighty":-5.987916,"marketCap":1427987292},{"date":"2026-08-07","current":-9.944083,"twenty":-11.060026,"median":-8.325975,"eighty":-5.988037,"marketCap":1444288517},{"date":"2026-08-14","current":-9.008172,"twenty":-11.059428,"median":-8.330997,"eighty":-5.993847,"marketCap":1479231870},{"date":"2026-08-21","current":-8.761948,"twenty":-11.05527,"median":-8.347715,"eighty":-5.99759,"marketCap":1438799532},{"date":"2026-08-28","current":-9.308444,"twenty":-11.025772,"median":-8.353948,"eighty":-6.007177,"marketCap":1528539599},{"date":"2026-09-02","current":-9.053213,"twenty":-11.023236,"median":-8.373482,"eighty":-6.007177,"marketCap":1486628029}],"updateTime":1788470357153},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVBP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636018499","title":"LifeSci Capital Remains a Buy on ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636018499","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636018499?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:46","pubTimestamp":1779036389,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on ArriVent BioPharma, Inc. yesterday and set a price target of $42.00. According to Ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635973714","title":"ArriVent BioPharma Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2635973714","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635973714?lang=en_us&edition=fundamental","pubTime":"2026-05-14 02:56","pubTimestamp":1778698560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 14:56 ET (18:56 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634255366","title":"ArriVent BioPharma Updates At-The-Market Equity Offering Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2634255366","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634255366?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:53","pubTimestamp":1778536380,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc. ( ($AVBP) ) has shared an update. On May 11, 2026, ArriVent BioPharma, Inc. filed a prospectus supplement with the U.S. Se...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-updates-at-the-market-equity-offering-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-updates-at-the-market-equity-offering-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","BK4585","AVBP","BK4588","EQR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634230051","title":"ArriVent Biopharma launches ATM offering for up to $250 million via Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2634230051","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634230051?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:44","pubTimestamp":1778532248,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma filed a prospectus supplement for its existing at-the-market offering program, authorizing sales of up to USD 250 million of common stock.Jefferies will act as sales agent for the share sales from time to time under an Open Market Sale Agreement dated Feb. 3, 2025.Program will operate off ArriVent’s automatic shelf registration statement on Form S-3ASR filed Feb. 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLbSdLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634230737","title":"Arrivent Biopharma Inc - Enters Open Market Sale Agreement for Offer and Sell Common Stock up to $250 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2634230737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634230737?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:42","pubTimestamp":1778532174,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O1JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634923041","title":"ArriVent Biopharma posts corporate presentation on late-stage oncology pipeline, firmonertinib lead program","url":"https://stock-news.laohu8.com/highlight/detail?id=2634923041","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634923041?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:34","pubTimestamp":1778531655,"startTime":"0","endTime":"0","summary":"ArriVent highlighted firmonertinib as lead program, with topline data expected in mid-2026 from global registrational Phase 3 FURVENT trial in first-line EGFR exon 20 insertion mutant NSCLC.FURVENT enrolled 398 patients versus target 375, with progression-free survival by blinded independent central review as primary endpoint.For first-line EGFR PACC mutant NSCLC, global Phase 3 ALPACCA targets 480 patients, comparing firmonertinib 240 mg once daily versus investigator’s choice of osimertinib or afatinib.ArriVent reported cash and cash equivalents of USD 326.4 million as of March 31, 2026.ADC pipeline update included ARR-217 in Phase 1 with dose-escalation completion planned in 2H 2026, alongside ARR-002 with US IND clearance and Phase 1 initiation planned in 2H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8tWg01:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237265","title":"ArriVent BioPharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237265?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:20","pubTimestamp":1778530817,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma Inc reports results for the quarter ended March 31 - Earnings SummaryArriVent BioPharma Inc AVBP.OQ reported a quarterly adjusted loss of 96 cents per share for the quarter ended Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634517237","title":"ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634517237","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634517237?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:12","pubTimestamp":1778530353,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.86) by 11.63 percent. This is a 49.47 percent increase over losses of $(1.90) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52468664/arrivent-biopharma-q1-eps-0-96-misses-0-86-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232590","title":"ArriVent Q1 net loss narrows 32.7% to $43.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232590","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232590?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:02","pubTimestamp":1778529733,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma posted a net loss of USD 43.3 million, narrowing from USD 64.4 million a year earlier; loss per share improved to USD 0.96 from USD 1.90.R&D expense fell to USD 37.6 million from USD 61.3 million, while G&A expense rose to USD 8.5 million from USD 5.5 million.Cash and investments totaled USD 326.4 million as of March 31, expected to fund operations into 4Q 2027.Topline Phase 3 monotherapy data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected in mid-2026; Phase 3 ALPACCA study in EGFR PACC mutant NSCLC continues enrolling globally.FDA cleared IND for ARR-002, with first patient dosing planned in 2H 2026; ARR-217 Phase 1 dose escalation in GI cancers continues after first patient was dosed in March 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL79SDf0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BN0W2V16.EUR","SG9999014013.SGD","AVBP","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014039.USD","LU0314104364.USD","NDAQ","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4588","LU2210149790.SGD","LU2210150020.SGD","SG9999014021.USD","BK4585","LU2095319765.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634368232","title":"Arrivent Biopharma Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634368232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634368232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529661,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA1FRJG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634325842","title":"Press Release: ArriVent BioPharma Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634325842","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634325842?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529660,"startTime":"0","endTime":"0","summary":"-- Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR. -- IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b. tetravalent ADC, advances into the clinic and plans to dose its first. patient in 2H 2026, initially for ovarian and endometrial cancers. -- ARR-002's superior anti-tumor activity and favorable tolerability vs.single-target or bivalent approaches in preclinical ovarian cancer models. Dr. Yao continued, \"We also presented preclinical data for our antibody-drug conjugate , ARR-002 at AACR. This novel MUC16/NaPi2b dual-targeting tetravalent ADC demonstrated synergistic anti-tumor activity compared to single-target and bivalent ADCs, along with a favorable tolerability profile, supporting its best-in-class potential. Following the recent clearance of our Investigational New Drug  application by the U.S. Food and Drug Administration , we plan to initially advance ARR-002 into the clinic for ovarian and endometrial cancers. Our balance sheet contin","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","AVBP","BK4080","BK4231","BK4139","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633468945","title":"ArriVent BioPharma Inc  expected to post a loss of 89 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633468945","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633468945?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:42","pubTimestamp":1778254927,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma Inc  expected to post a loss of89cents a share - Earnings Preview ArriVent BioPharma Inc AVBP.OQ AVBP.O is expected to  show no change in quarterly revenue when it reports  results ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1X5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633304174","title":"H.C. Wainwright Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633304174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633304174?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:59","pubTimestamp":1778237996,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns reiterated a Buy rating on ArriVent BioPharma, Inc. today and set a price target of $44.00. According to TipRa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633787221","title":"ArriVent Biopharma announces FDA clearance of ARR-002 NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2633787221","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633787221?lang=en_us&edition=fundamental","pubTime":"2026-05-08 02:45","pubTimestamp":1778179502,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) announced clearance of an investigational new drug application by the FDA for ARR-002, a MUC16/NaPi2b targeting tetravale...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrivent-biopharma-announces-fda-clearance-of-arr-002-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrivent-biopharma-announces-fda-clearance-of-arr-002-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","BK4585","BK4588","ARR","LABU","BK4110","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633714469","title":"BRIEF-Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2633714469","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633714469?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:05","pubTimestamp":1778155509,"startTime":"0","endTime":"0","summary":"BRIEF-Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial CancersMay 7 (Reuters) - Arrivent Biopharma Inc AVBP.O:ARR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K0OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633114430","title":"ArriVent wins FDA IND clearance for ARR-002 cancer antibody-drug conjugate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633114430","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633114430?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:04","pubTimestamp":1778155448,"startTime":"0","endTime":"0","summary":"ArriVent Biopharma secured FDA clearance of an IND for ARR-002, a tetravalent MUC16/NaPi2b-targeting antibody-drug conjugate initially aimed at ovarian and endometrial cancers.Phase 1 trial start expected in 2H 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL31ht7Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","IE00BKPKM429.USD","AVBP","BK4112","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","BK4139","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2T93.GBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633417411","title":"Arrivent Biopharma Inc - Phase 1 Initiation for Arr-002 Expected in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633417411","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633417411?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:01","pubTimestamp":1778155282,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K0OK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633417291","title":"Arrivent Announces Ind Clearance for Novel Tetravalent Muc16/Napi2b Targeting ADC Arr-002 With Initial Focus in Ovarian and Endometrial Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2633417291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633417291?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:01","pubTimestamp":1778155282,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K0OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631535682","title":"ArriVent Biopharma announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2631535682","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631535682?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:16","pubTimestamp":1777407402,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma schedules 2026 annual stockholders meeting for June 18, 2026, to be held virtually.Shareholders will vote on election of three directors to three-year terms expiring in 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL1TLgBt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629847081","title":"ArriVent BioPharma Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2629847081","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629847081?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:14","pubTimestamp":1777040040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2026 10:14 ET (14:14 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":55,"code":"91000000","status":"200"}]}}